News and Activities
Hot Off The Press.
Press Releases
Incorporating Straticyte™ Could Enhance Assessment of Cancer Risk in Oral Lesions
MaRS Discovery District, Toronto, ON; December 14, 2020 - Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON, announces today that Oral Cancer and the Race Against Time: Use of Psoriasin (S100A7) as a Predictive Marker to Enhance Assessment of Cancer...
Straticyte™ Observational Study Registered on ClinicalTrials.gov
MaRS Discovery District, Toronto, ON; November 10, 2020 - Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON, announces today that the company has registered an observational study on ClinicalTrials.gov, a database of privately and publicly funded...
Straticyte™ Presented at the 7th World Congress of the International Academy of Oral Oncology
MaRS Discovery District, Toronto, ON; September 4, 2019 - Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON, announces today that an abstract and poster titled "Clinical Management of Patients with Oral Epithelial Dysplasia and Elevated Straticyte™...
Dr. Anthony B. Morlandt, Assistant Professor Department of Oral and Maxillofacial Surgery of the University of Alabama at Birmingham, joins Proteocyte AI’s Clinical Advisory Board
Toronto, ON; June 12, 2018 - Proteocyte AI, a company designing tests that predict the progression of premalignant lesions, announced today that Dr. Anthony B. Morlandt, Assistant Professor, Chief Oral Oncology, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, has...